You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


MSD’s Keytruda given go-ahead by SMC

MSD’s Keytruda has received a recommendation from the Scottish Medicines Consortium (SMC) for the adjuvant treatment of adults and adolescents, aged 12 years and older, with stage IIB or IIC melanoma skin cancer.